CARDIZEM Drug Patent Profile
✉ Email this page to a colleague
When do Cardizem patents expire, and what generic alternatives are available?
Cardizem is a drug marketed by Biovail, Biovail Labs Intl, and Bausch. and is included in six NDAs.
The generic ingredient in CARDIZEM is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cardizem
A generic version of CARDIZEM was approved as diltiazem hydrochloride by TEVA on May 31st, 1995.
Summary for CARDIZEM
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 6 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 58 |
| Clinical Trials: | 10 |
| Patent Applications: | 4,277 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CARDIZEM |
| What excipients (inactive ingredients) are in CARDIZEM? | CARDIZEM excipients list |
| DailyMed Link: | CARDIZEM at DailyMed |
Recent Clinical Trials for CARDIZEM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assiut University | Early Phase 1 |
| CAMC Health System | Phase 4 |
| University of South Florida | N/A |
Pharmacology for CARDIZEM
| Drug Class | Calcium Channel Blocker |
| Mechanism of Action | Calcium Channel Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for CARDIZEM
US Patents and Regulatory Information for CARDIZEM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biovail | CARDIZEM | diltiazem hydrochloride | INJECTABLE;INJECTION | 020792-001 | Sep 5, 1997 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-006 | Feb 6, 2003 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Bausch | CARDIZEM | diltiazem hydrochloride | TABLET;ORAL | 018602-004 | Dec 8, 1986 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Bausch | CARDIZEM | diltiazem hydrochloride | TABLET;ORAL | 018602-001 | Nov 5, 1982 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Bausch | CARDIZEM CD | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020062-005 | Aug 24, 1999 | AB3 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CARDIZEM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch | CARDIZEM | diltiazem hydrochloride | TABLET;ORAL | 018602-003 | Dec 8, 1986 | ⤷ Try a Trial | ⤷ Try a Trial |
| Bausch | CARDIZEM | diltiazem hydrochloride | TABLET;ORAL | 018602-004 | Dec 8, 1986 | ⤷ Try a Trial | ⤷ Try a Trial |
| Bausch | CARDIZEM | diltiazem hydrochloride | TABLET;ORAL | 018602-004 | Dec 8, 1986 | ⤷ Try a Trial | ⤷ Try a Trial |
| Bausch | CARDIZEM | diltiazem hydrochloride | TABLET;ORAL | 018602-001 | Nov 5, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Bausch | CARDIZEM | diltiazem hydrochloride | TABLET;ORAL | 018602-004 | Dec 8, 1986 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CARDIZEM
See the table below for patents covering CARDIZEM around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| United Kingdom | 1040545 | ⤷ Try a Trial | |
| Switzerland | 516587 | Verfahren zur Herstellung von Benzothiazepinderivaten | ⤷ Try a Trial |
| Spain | 359545 | ⤷ Try a Trial | |
| Philippines | 9620 | MID-TERM ABORTION WITH PROSTAGLANDINS | ⤷ Try a Trial |
| Denmark | 131462 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
